Rituxan

E46089
CD20-directed cytolytic antibody biologic drug chimeric monoclonal antibody monoclonal antibody

Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.

Jump to: Surface forms Statements Referenced by

Observed surface forms (3)

Surface form Occurrences
rituximab 2
Ocrevus 1
Truxima 1

Statements (52)

Predicate Object
instanceOf CD20-directed cytolytic antibody ⓘ
biologic drug ⓘ
chimeric monoclonal antibody ⓘ
monoclonal antibody ⓘ
ATCCode L01FA01 ⓘ
combinationRegimen R-CHOP ⓘ
commonAdverseEffect chills ⓘ
fever ⓘ
infections ⓘ
infusion-related reactions ⓘ
neutropenia ⓘ
contraindicatedIn known severe hypersensitivity to rituximab ⓘ
developedBy Biogen ⓘ
Genentech ⓘ
firstApprovedBy Food and Drug Administration ⓘ
surface form: U.S. Food and Drug Administration
firstApprovedYear 1997 ⓘ
hasBiosimilar Riabni ⓘ
Ruxience ⓘ
Rituxan self-linksurface differs ⓘ
surface form: Truxima
hasBlackBoxWarning hepatitis B virus reactivation ⓘ
infusion reactions ⓘ
progressive multifocal leukoencephalopathy ⓘ
severe mucocutaneous reactions ⓘ
hasDrugClass antineoplastic agent ⓘ
immunosuppressive agent ⓘ
hasGenericName rituximab ⓘ
hasINN Rituxan self-linksurface differs ⓘ
surface form: rituximab
hasMoleculeType IgG1 kappa monoclonal antibody ⓘ
indicatedFor chronic lymphocytic leukemia ⓘ
diffuse large B-cell lymphoma ⓘ
follicular lymphoma ⓘ
granulomatosis with polyangiitis ⓘ
microscopic polyangiitis ⓘ
non-Hodgkin lymphoma ⓘ
pemphigus vulgaris ⓘ
rheumatoid arthritis ⓘ
isChimericOf human antibody ⓘ
mouse antibody ⓘ
marketedBy Biogen ⓘ
Genentech ⓘ
mechanismOfAction binds CD20 on B cells ⓘ
induces B-cell lysis ⓘ
induces apoptosis of B cells ⓘ
mediates antibody-dependent cellular cytotoxicity ⓘ
mediates complement-dependent cytotoxicity ⓘ
oftenUsedWith cyclophosphamide ⓘ
doxorubicin ⓘ
prednisone ⓘ
vincristine ⓘ
routeOfAdministration intravenous infusion ⓘ
targets B lymphocytes ⓘ
CD20 protein ⓘ

Referenced by (6)

Full triples — surface form annotated when it differs from this entity's canonical label.

Rituxan → hasBiosimilar → Rituxan self-linksurface differs ⓘ
this entity surface form: Truxima
this entity surface form: rituximab
Rituxan → hasINN → Rituxan self-linksurface differs ⓘ
this entity surface form: rituximab
Genentech → notableProduct → Rituxan ⓘ
Roche → product → Rituxan ⓘ
Roche → product → Rituxan ⓘ
this entity surface form: Ocrevus